<p>For Immediate Release</p><p>Wednesday, September 20, 2006 Cambridge Isotope Laboratories, Inc. (CIL) Contacts: Dr. Peter Moll, Managing Director, ABX Peter E. Dodwell, President, CIL Maureen A. Duffy, Vice President, Sales, CIL ABX Tel: +49 (35) 28-40-41-62 CIL Tel: 978-749-8000 E-Mail: [email protected] [email protected] [email protected]</p><p>CAMBRIDGE ISOTOPE LABORATORIES (CIL) ACQUIRES NUCLEAR MEDICINE CHEMICAL MANUFACTURER ABX ADVANCED BIOCHEMICAL COMPOUNDS (ABX)</p><p>Boston,Massachusetts: CIL, the world’s leader in the manufacturing of stable isotope labeled research chemicals and a leading supplier of 18O water to PET nuclear pharmacies, has acquired 100% of the stock of ABX Advanced Biochemical Compounds of Radeburg, Germany. According to CIL’s President, Peter Dodwell, “CIL’s union with ABX demonstrates both companies commitment to utilizing shared resources to speed the development of new tracers for nuclear medicine applications including PET, SPECT and MRI.”</p><p>ABX specializes in the development and manufacturing of chemicals for nuclear medicine applications, such as PET and SPECT, and is the primary producer of GMP Mannose Triflate, an active pharmaceutical ingredient (API) for producing 18FDG for PET. In addition, ABX is developing GMP precursor kits for new tracers, such as FLT, and offers a wide selection of research precursors, suitable for clinical trials, for new PET compounds under development.</p><p>Page 1 of 2 CIL is the premier supplier of stable isotopes for research applications in proteomics, genomics, molecular biology, metabolic research, clinical and diagnostic research and ultra trace environmental analysis. For 25 years CIL has provided over 15,000 different research compounds to its base of 35,000 to 40,000 medical, pharmaceutical, academic and government customers. </p><p>This acquisition brings together CIL’s synthetic expertise, GMP experience and long history of serving the research customer market and ABX’s reputation for synthesis of high quality GMP and non-GMP nuclear medicine compounds and precursors. “There is a definite synergy between the two groups and we are happy to join CIL and merge our strengths in synthetic chemistry and GMP production,” stated Peter Moll, Managing Director of ABX. The combination will provide ABX additional technical resources to further develop a full range of products and services in PET and other imaging modalities, including FDG kit development, GMP kits for new tracers, contract research and peptide synthesis. In addition, CIL anticipates providing ABX a second separate, independent GMP manufacturing site for Mannose Triflate located in the United States.</p><p>The key managers and employees of ABX are continuing with the Company.</p><p>Page 2 of 2</p>